SOD1 and Bardet-Biedl syndrome: We have demonstrated that BBS treatment results in decrease in mutant SOD1 levels not only in motor neuron cell line NSC34 but also in primary astroglial cells; therefore it is possible that reduction in neuroinflammation occurs as a result of reduction in the levels of mutant SOD1.